Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator - Wikidata - awgldk - TriplyDB

Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator

Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator

http://www.wikidata.org/entity/Q37263891

about

Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier The Effect of Polymeric Nanoparticles on Biocompatibility of Carrier Red Blood Cells Flow-dependent channel formation in clots by an erythrocyte-bound fibrinolytic agent.Targeting of a mutant plasminogen activator to circulating red blood cells for prophylactic fibrinolysis Red blood cell-coupled tissue plasminogen activator prevents impairment of cerebral vasodilatory responses through inhibition of c-Jun-N-terminal kinase and potentiation of p38 mitogen-activated protein kinase after cerebral photothrombosis in the n Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation.Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells.The shape of things to come: importance of design in nanotechnology for drug delivery.Signaling, delivery and age as emerging issues in the benefit/risk ratio outcome of tPA For treatment of CNS ischemic disorders.RBC-coupled tPA Prevents Whereas tPA Aggravates JNK MAPK-Mediated Impairment of ATP- and Ca-Sensitive K Channel-Mediated Cerebrovasodilation After Cerebral Photothrombosis Advanced drug delivery systems for antithrombotic agents.Red blood cells-coupled tPA prevents impairment of cerebral vasodilatory responses and tissue injury in pediatric cerebral hypoxia/ischemia through inhibition of ERK MAPK activation Erythrocyte-bound tissue plasminogen activator is neuroprotective in experimental traumatic brain injury.Drug delivery by red blood cells: vascular carriers designed by mother nature.Bio-inspired, bioengineered and biomimetic drug delivery carriers.Vascular targeting of antithrombotic agents.Drug delivery by red blood cells.Coagulopathy after traumatic brain injury.Approaches to erythrocyte-mediated drug delivery.Erythrocytes-based synthetic delivery systems: transition from conventional to novel engineering strategies.Engineering of plasminogen activators for targeting to thrombus and heightening thrombolytic efficacy.Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.Drug delivery by erythrocytes: "Primum non nocere".No-reflow phenomenon and endothelial glycocalyx of microcirculation.The spatial dynamics of fibrin clot dissolution catalyzed by erythrocyte-bound vs. free fibrinolytics.Cardiological biopharmaceuticals in the conception of drug targeting delivery: practical results and research perspectives.Soluble urokinase receptor conjugated to carrier red blood cells binds latent pro-urokinase and alters its functional profile.Antioxidant enzymes as potential targets in cardioprotection and treatment of cardiovascular diseases. Enzyme antioxidants: the next stage of pharmacological counterwork to the oxidative stress.Cell-Based Drug Delivery and Use of Nano-and Microcarriers for Cell Functionalization.Recent advances in targeted delivery of tissue plasminogen activator for enhanced thrombolysis in ischaemic stroke.Nanoparticle Properties Modulate Their Attachment and Effect on Carrier Red Blood Cells.

P2860

Q26801300-C31B6A08-F3A8-46DF-AFA7-0F4E19A9382A Q28550941-42FA568C-8896-4B56-8FE2-D3FF2D4A82D7 Q30500397-64DA5AC4-F5C7-49EF-AA10-41B34FCDE5E8 Q33714889-8B1CF5C4-31E6-4101-AADE-EC6C07F1CE4C Q33734359-50F616D6-408C-453B-ADFC-2B7C481BEE90 Q33944248-11D27531-8C1A-4667-B401-1C5D65E506F8 Q34028841-2F8F670C-5259-4985-92B6-F9A40ECF09B1 Q36128678-D8F16BA6-BFE4-4CC5-902F-C4F51FACDC30 Q36307742-71B202F5-2E5B-4BE5-A287-0482723A2BA8 Q36748046-6F244EB8-2173-44D4-830F-3AD3DC60D02A Q37132620-38985095-5484-4790-ADA3-EFE00A340853 Q37285884-E1E25B8B-3E73-45AB-975B-00AA13AF358A Q37397703-9A2E1D24-2B90-4588-8938-CF3601770B4C Q37700751-92AFDD55-7E17-4AC8-89B1-E030302ED24E Q37896455-2F0111A7-F41F-449E-B174-1164C5CCD8B0 Q37902114-5460A0C8-FC7B-4794-9003-04253852DD0B Q37902115-5780FC32-F643-4C73-9E63-CDA71A0D437C Q37981549-AD8A1B10-3A20-47D7-AF51-9E1A4EAE80BB Q38189095-DA7C7A7D-0DB1-493F-8F57-50845701FE3E Q38218799-63C1D9ED-B342-4CA4-83B6-F3CD09957870 Q38527633-8B286150-26EE-4E16-973D-7750F839B3DD Q38760096-047EB1A5-3B6D-4FA6-8515-7CCD9A6A5DBC Q38972974-AC8D827E-AED0-4E12-8C22-D8A7A9ED7E8B Q39011174-F3E7DCDE-A54A-4F85-8B3D-2585D8FEA465 Q39724415-11C5E54C-AE6A-4464-9BBD-06313D69AB11 Q41302329-328AA25E-7915-4E3E-AFAB-5C3068A23C33 Q41398638-2DBE64E1-4F7A-4618-A7D3-01B4C5D032CE Q42028534-1E39CA51-C418-429B-87DE-1A0BFD3478BA Q42183251-6AFC6C3F-541D-4A91-9FA1-B8FC9470CE5C Q47295354-BF3F9BD7-9037-4698-8B79-1D6B58805A97 Q48159250-90E83233-7385-46AB-9E72-A97EA6641B21 Q49351130-80E64770-0859-442A-84FE-79F52C0CB882

P2860

Cerebrovascular thromboprophylaxis in mice by erythrocyte-coupled tissue-type plasminogen activator

http://www.wikidata.org/entity/Q37263891

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 15 September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Cerebrovascular thromboprophyl ...... sue-type plasminogen activator

@en

Cerebrovascular thromboprophyl ...... ue-type plasminogen activator.

@nl

type

label

Cerebrovascular thromboprophyl ...... sue-type plasminogen activator

@en

Cerebrovascular thromboprophyl ...... ue-type plasminogen activator.

@nl

prefLabel

Cerebrovascular thromboprophyl ...... sue-type plasminogen activator

@en

Cerebrovascular thromboprophyl ...... ue-type plasminogen activator.

@nl

P1433

Q37263891-4EEB7495-3C61-45F8-BEEB-900AB5AB9A1A

P1476

Q37263891-C7464698-02CD-47AC-9BFB-BCCDFEF7D942

P2093

Q37263891-053879A6-3FDD-4A95-8685-73AF1C53E20D

Q37263891-217A401C-D9BC-4799-8FDF-B01E2D5294DC

Q37263891-254FCA1E-C59C-4AC8-B105-DF847202A098

Q37263891-29080E2E-DB72-40CE-A6AE-C56DF19F9838

Q37263891-35CE2C6E-9AD5-492D-8E59-FC1FB4A6A684

Q37263891-373B6EE5-BBEF-452F-83C8-80649B478CD9

Q37263891-3C5B1AC5-C330-4F24-9DFE-6F99A9DAC150

Q37263891-5C84E9E7-01EE-47AC-8820-BD2DEDEEF978

Q37263891-6FE5BC6C-2A09-4DF0-A00B-B7B4AB6A05BE

Q37263891-E450AB15-F07B-4CC5-9F93-0391D9D16019

P2860

Q37263891-05D8E2D8-378F-4210-A898-388C7B39E3A7

Q37263891-0846607F-C77E-4455-AEDA-EB80C6E785CB

Q37263891-09D419CA-D1AF-4ADE-847F-6AA7C18EEF18

Q37263891-16A0E8F8-C1DD-4665-80C2-840DA8E1888B

Q37263891-1B295AC0-E6A9-4187-A52E-62BB243755B4

Q37263891-1CE2ABB9-2089-45FE-A8A0-235D7B09E13E

Q37263891-2064BAC4-7D0F-415C-98DD-E57F34142EDA

Q37263891-24CFBAC6-A9C0-4A6E-8A2D-226213F5E37F

Q37263891-29485484-EC67-47CB-8A35-CBAECD9C0FB3

Q37263891-29D17905-88E2-4613-BC8C-B27CB90C60EF

P304

Q37263891-F7171E16-9D3E-4DD1-AFE4-1F4C20F3B879

P31

Q37263891-0CE2AAE7-892B-47A9-BF42-EEC1AAD98424

P356

Q37263891-AD31F818-128B-4A75-AEC7-D2C76F26A7C5

P407

Q37263891-77CDE152-AAE2-4F3B-AC91-5ED976EA60ED

P433

Q37263891-4C26020D-03FD-4426-BC0B-3D3930D2A1A6

P478

Q37263891-6B8D60EB-7233-40CA-B8C7-74E996DDE627

P577

Q37263891-0E5ECA85-2CBF-4DEE-B906-81DD2BD7DBEA

P5875

Q37263891-3D01D54A-BC2C-4588-8A27-8E2D296C7225

P698

Q37263891-24985A96-D308-4599-8242-E23374B5743F

P932

Q37263891-902AD44C-92F7-43E9-9383-4525B09CE4A8

P356

CIRCULATIONAHA.107.750257

P1433

P1476

Cerebrovascular thromboprophyl ...... sue-type plasminogen activator

@en

P2093

Bi-Sen Ding

http://www.w3.org/2001/XMLSchema#string

Dmitriy Atochin

http://www.w3.org/2001/XMLSchema#string

Douglas B Cines

http://www.w3.org/2001/XMLSchema#string

Juan-Carlos Murciano

http://www.w3.org/2001/XMLSchema#string

Kristina Danielyan

http://www.w3.org/2001/XMLSchema#string

Kumkum Ganguly

http://www.w3.org/2001/XMLSchema#string

Paul L Huang

http://www.w3.org/2001/XMLSchema#string

Scott E Kasner

http://www.w3.org/2001/XMLSchema#string

Sergei Zaitsev

http://www.w3.org/2001/XMLSchema#string

Vladimir R Muzykantov

http://www.w3.org/2001/XMLSchema#string

P2860

Application of current guidelines to the management of unstable angina and non-ST-elevation myocardial infarction

Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery

The cytoprotective protein C pathway

Human complement receptor type 1-directed loading of tissue plasminogen activator on circulating erythrocytes for prophylactic fibrinolysis

Mouse model of microembolic stroke and reperfusion.

Fibrin affinity of erythrocyte-coupled tissue-type plasminogen activators endures hemodynamic forces and enhances fibrinolysis in vivo.

Subclinical embolization after carotid artery stenting: new lesions on diffusion-weighted magnetic resonance imaging occur postprocedure.

Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.

Recognition of the importance of embolization in atherosclerotic vascular disease.

Cardiopulmonary bypass and cerebral injury in adults.

P304

1442-1449

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/CIRCULATIONAHA.107.750257

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2008-09-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23258137

http://www.w3.org/2001/XMLSchema#string

P698

18794394

http://www.w3.org/2001/XMLSchema#string

P932

2711540

http://www.w3.org/2001/XMLSchema#string